Haldol (Intramuscular)

Quick links

Choose a section

Quick links to important sections

Advertisements

Haldol (Intramuscular)

Selected form

Advertisements

Overview of Haldol (Intramuscular)

Quick Facts

Property Description
Active Ingredient Haloperidol Decanoate
Form Injectable Suspension (Depot Formulation)
Pharmacological Class First-Generation Antipsychotic (FGA)
General Purpose Promoting consistent mental stability
Origin Synthetic, Butyrophenone Derivative

What Type of Medicine is Haloperidol Decanoate?

Haloperidol Decanoate, the active compound in Haldol (Intramuscular), is a synthetic, single-ingredient medication classified as a First-Generation Antipsychotic (FGA), a type of conventional psychotropic agent. The compound belongs to the butyrophenone derivative chemical family. As a high-potency agent, its fundamental mechanism involves strong antagonism of central dopamine D2 receptors, which helps balance neurochemical signaling in the brain. Long-acting injectable antipsychotics like this formulation are utilized for the long-term maintenance of stability in patients. This medicine is used to provide a sustained mental equilibrium over time. Common brand names with this same formulation include Haldol Decanoate and Haloperidol LA (Long-Acting).

Composition and Purpose of the Long-Acting Injectable (LAI) Form

The product is supplied as an injectable suspension and a specialized depot formulation intended exclusively for intramuscular injection. The composition features the active compound, Haloperidol, which is chemically altered into the decanoate ester and suspended within an oily vehicle, commonly sesame oil, along with a preservative like benzyl alcohol. The decanoate esterification makes Haloperidol Decanoate a prodrug that is gradually released from the muscle tissue into the systemic circulation over an extended period. This specialized long-acting form is designed to improve adherence to treatment plans compared to daily oral regimens. This design ensures continuous, stable pharmacological action, which is intended to maintain consistent neurochemical equilibrium and is often prioritized for patient groups requiring reliable long-term support.

Regulatory References

  1. Haloperidol Decanoate DailyMed Information
  2. MedlinePlus Haloperidol Injection
Advertisements

What side effects are possible with Haldol (Intramuscular)?

Possible Side Effects and Safety Information

Regulatory documentation outlines the official safety characteristics of Haloperidol Decanoate, focusing on adverse reactions categorized by frequency and the body system affected. The safety profile is significantly shaped by neurological effects, including the class of movement disorders known as Extrapyramidal Symptoms (EPS), with Extrapyramidal Disorder being classified as a Very Common effect in regulatory documents.

Key adverse reactions, classified as Common, include Parkinsonism, Akathisia (involuntary restlessness), Tremor, Somnolence, Sedation, Constipation, and Injection Site Reaction for the long-acting injectable form.


Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the potential for serious adverse reactions, which, though often rare, require regulatory classification. These include the risk of Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome involving muscle rigidity and fever, and serious cardiovascular events such as QT-prolongation, Torsades de pointes, and Sudden Death.

Safety notes tied to exposure indicate that the risk of Tardive Dyskinesia, a potentially irreversible movement disorder, is associated with the duration of treatment and the total cumulative dose. The FDA label includes a Black Box Warning regarding an increased risk of death when the drug is used in elderly patients with dementia-related psychosis.

The medicine is officially contraindicated for use in patients with pre-existing conditions such as Parkinson's Disease, certain Cardiac Arrhythmias, and those taking other QT-prolonging medicinal products. These safety domains structure the official risk communication, focusing on the high frequency of neurological effects alongside rare, critical systemic risks and population-specific limitations.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

A Haloperidol Decanoate overdose is officially documented as presenting with an exaggeration of known pharmacological effects, often leading to severe or life-threatening manifestations. Immediate medical attention must be sought for any suspected overdose, as directed by government regulatory authorities.

Documented Clinical Manifestations

Overdose may result in profound neurological compromise, including severe central nervous system (CNS) depression that can progress to coma, seizures, and severe extrapyramidal reactions (EPS) such as muscle rigidity and tremor. Cardiovascular signs often involve marked hypotension (low blood pressure) and tachycardia (rapid heart rate). Anticholinergic symptoms are also noted.

Severe and Life-Threatening Outcomes

Regulatory labeling emphasizes serious cardiovascular risk, including QT-prolongation, Torsades de Pointes, and other ventricular arrhythmias, which may result in sudden death. The potential for a shock-like state secondary to severe hypotension is also recognized. Overdose is officially associated with doses higher than recommended.

Emergency Management

No specific antidote is known for Haloperidol Decanoate overdose. Management is officially defined as symptomatic and supportive, requiring continuous cardiac monitoring with repeated ECG assessment due to the arrhythmia risk. Treating severe hypotension involves intravenous fluids and suitable vasopressors; however, regulatory documents state that epinephrine should not be used.

Advertisements

Therapeutic Uses of Haldol (Intramuscular)

What Haldol (Intramuscular) Treats: Main Uses and Benefits

The primary role of intramuscular (IM) Haldol is to provide short-term symptomatic assistance during acute episodes of severe mental distress and behavioral disturbance. This use is recognized particularly in situations where symptomatic assistance is needed immediately for agitation. It is commonly used across conditions presenting with acute episodes where patients experience heightened distress.

IM Haldol is generally applied in contexts marked by increased discomfort or tension and plays a role in managing symptoms related to: acute agitation and aggression, severe psychotic thought disturbances (delusions and hallucinations), and sometimes symptoms of increased neurological or muscular activity (severe tics). This intervention offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.


Quick Fact: Relief for Acute Agitation

IM Haldol is often used during phases when symptoms become more noticeable, specifically addressing symptom clusters that may become intense or disruptive. This provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Haldol (Intramuscular)

Official regulatory guidelines strictly define the populations permitted and prohibited from using Haldol (Intramuscular) based on specific age, condition, and physiological status.


Absolute Contraindications

This medication is strictly contraindicated (must not be used) in patients with specific neurological conditions, including Parkinson's disease, Dementia with Lewy bodies, and Progressive Supranuclear Palsy. It is also prohibited for patients in a state of severe toxic central nervous system depression or coma, or those with a known hypersensitivity to the drug or its components. Patients with serious underlying cardiovascular disorders like known QTc interval prolongation or uncompensated heart failure are also excluded from use.


Restricted and Non-Established Use

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents below 18 years of age.
  • Geriatric Use: The product is not approved for treating psychosis related to dementia in elderly patients.
  • Organ Function: Caution is advised for patients with hepatic impairment (liver disease) or severe renal impairment.
  • Reproductive Status: Use during pregnancy is advised only if the benefit clearly justifies the potential risk to the fetus. Infants should not be nursed during treatment.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Haldol (Intramuscular) is focused on critical pharmacokinetic and pharmacodynamic interactions that impose specific constraints on co-administration.

Interaction Type Interacting Substance / Class Regulatory Constraint
Cardiac Risk Drugs that prolong the QTc interval Must be avoided due to the risk of QTc prolongation and Torsades de Pointes.
Exposure Altering CYP3A4 / CYP2D6 Inhibitors Can increase haloperidol plasma concentrations, posing a risk of cardiac events.
Exposure Altering Enzyme Inducers (e.g., Carbamazepine, Rifampin) Can cause a significant reduction in haloperidol plasma concentrations.
Neurological Risk Lithium Requires close monitoring for signs of encephalopathic syndrome and prompt discontinuation if signs appear.
CNS Effects Alcohol, CNS Depressants Avoid due to the risk of additive CNS depressant effects and hypotension.
Antagonism Dopaminergic Drugs (e.g., Levodopa) May impair the antiparkinson effects of these agents.

The prescribing information mandates the avoidance of combinations that increase haloperidol exposure or increase the risk of cardiac electrical activity changes. The metabolism via CYP3A4 and CYP2D6 defines significant pharmacokinetic constraints that lead to necessary exposure modification awareness. Furthermore, Haloperidol IM is officially contraindicated in patients with Parkinson's disease or Dementia with Lewy Bodies, and Epinephrine is not recommended for treating related hypotension. These official statements categorize interactions based on severity and required patient-specific action.

Advertisements

Mechanism of Action

Haloperidol, following intramuscular administration, distributes into the central nervous system to exert its pharmacodynamic effect. The primary molecular targets are the D2 dopamine receptors, predominantly localized in the mesolimbic and striatal pathways. Haloperidol functions as a competitive antagonist at these D2 receptors. By binding with high affinity, the drug blocks the orthosteric binding site, preventing the endogenous agonist, dopamine, from initiating signaling.

This antagonistic interaction at the D2 receptor inhibits the associated Gi-protein coupled signaling cascade. The subsequent Gi protein activation is reduced, resulting in less inhibition of adenylyl cyclase activity. This leads to an increase in the intracellular conversion of ATP to cyclic AMP (cAMP) compared to the state of full D2 receptor activation.

Haloperidol also exhibits measurable antagonistic activity at D4 dopamine receptors and alpha1-adrenergic receptors, contributing to the overall molecular profile. The collective blockade of postsynaptic dopamine receptors modulates neurotransmission in key brain circuits, resulting in a system-level alteration of dopaminergic outflow and neuronal activity in the basal ganglia and limbic system.

Advertisements

Dosage and Administration Information

How to use Haldol (Intramuscular)

Haldol (haloperidol) is available as both a short-acting injection (haloperidol lactate) and a long-acting depot injection (Haldol Decanoate).

Administration

Both forms are administered by a healthcare professional as a deep intramuscular (IM) injection. The decanoate formulation is typically injected into the gluteal region, and subsequent doses should alternate sides.

  • Do not administer either form of Haldol intramuscular injection intravenously (IV). IV administration of haloperidol is not an approved use, and is associated with a higher risk of serious adverse cardiac effects, such as QT-prolongation.
  • For Haldol Decanoate, a 21-gauge needle is generally recommended, and the injection volume should not exceed 3 mL per site.

Dosage and Regimen

Your specific dosage and regimen will be determined by your doctor based on your clinical history, symptoms, and previous response to oral haloperidol. Treatment initiation and dose adjustments must occur under close clinical supervision.

Type of Injection Typical Dosing Schedule
Haldol Decanoate (Long-Acting) Administered once every 3 to 4 weeks.
Haldol Lactate (Short-Acting) Used for acute control; may be given every 4 to 8 hours as needed, with a maximum recommended daily dose not to exceed 20 mg.

For the long-acting Decanoate formulation, the initial dose is generally based on a conversion from your previous daily dose of oral haloperidol, and subsequent maintenance doses are adjusted every four weeks as needed. Patients may require temporary supplemental oral haloperidol during the transition or dose adjustments.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Haldol (Intramuscular)


Evidence for Use in Acute Agitation Associated with Schizophrenia

Research has explored the evaluation of Haldol (Intramuscular) in studies involving individuals experiencing acute or disruptive episodes of agitation associated with schizophrenia. Research has primarily examined clinical trials that focused on short-term symptom changes, typically within the first few hours after the medication was given. These studies help contribute to understanding what outcomes related to physical discomfort and outcomes describing episodic or acute changes were observed in the studied populations. The findings generally describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level. Crucially, evidence quality varies across studies, and research does not determine whether an individual will respond similarly.


Evidence for Use in Acute Agitation Associated with Bipolar Disorder

Research has explored the evaluation of Haldol (Intramuscular) in people experiencing conditions characterized by fluctuating or episodic manifestations, specifically the severe, acute agitation that may occur during manic or mixed episodes of bipolar I disorder. The evidence suggests that the medication was evaluated in research contexts involving fluctuating or unstable symptoms where outcomes related to systemic or functional imbalance were monitored within short time frames. The data show patterns related to short-term changes in these episodes, but findings were mixed when trying to define a single, consistent response pattern across all trials. The follow-up durations were limited in many of these studies.


Long-term Studies and Follow-up

Research has explored what happens after the immediate, short-term evaluation, but evidence is limited regarding outcomes tracked over many weeks or months. Currently, long-term effects are not fully established, and data for certain groups remain insufficient. The research that does exist contributes to the broader evidence landscape by describing patterns observed in the studies related to outcomes reflecting daily functioning or activity level after the acute phase. There is limited information for long-term outcomes from studies specifically on the intramuscular form.


What is Still Uncertain About Haldol (Intramuscular)

While many studies have contributed to the broader evidence landscape, several areas where certainty remains low exist. One key area is that comparative evidence is lacking regarding the outcomes of Haldol (Intramuscular) in relation to other treatments. Also, the research exploring outcomes monitoring physiological strain or stress and patient-reported outcomes describing perceived discomfort appears to have significant gaps. Research is ongoing, but the lack of long-term and comparative data means the evidence highlights what is known — and what is still uncertain.

Key Studies & References Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium - GOV.UK (Regulatory advice on special populations)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Haldol (Intramuscular) (FAQ)

Q: How do I switch from taking oral Haldol pills to the long-acting injection?

According to official product information, the initial dosage of the long-acting Haldol Decanoate injection is determined by a healthcare provider based on the individual's previous daily dosage of oral haloperidol. Official information notes that patients may require temporary supplemental oral haloperidol during the transition or dose adjustment period.

Q: What is the difference between Haldol Lactate (short-acting) and Haldol Decanoate (long-acting)?

Regulatory documents indicate that the short-acting Haldol Lactate is typically used for the acute control of severely agitated patients, often given on an as-needed basis every few hours. In contrast, the long-acting Haldol Decanoate is designed for maintenance therapy in patients who require prolonged antipsychotic treatment, with doses typically scheduled every four weeks.

Q: How long does it take for the Haldol Decanoate injection to start working?

Studies and official information indicate that Haldol Decanoate is a prodrug, meaning it releases the active medicine slowly from the muscle over time. The regulatory filing notes that the active compound reaches its highest concentration in the bloodstream (peak plasma concentration) about six days after the injection is administered.

Q: Does the Decanoate injection contain an oil, and does that matter?

Yes, official product information states that the injectable suspension is contained within an oily vehicle, such as sesame oil. This oily base supports the product's design, which allows the medicine to be released slowly from the muscle tissue, defining it as a long-acting depot injection.

Q: Can I drink alcohol while I am on the Haldol injection?

Regulatory documents state that alcohol use is to be avoided while the patient is on this medication. Combining alcohol with haloperidol can increase the central nervous system (CNS) depressant effects, which may lead to serious side effects like excessive drowsiness or low blood pressure (hypotension).

Q: What should I do if I miss an appointment for my Haldol Decanoate injection?

In the event a scheduled injection appointment is missed, contact with a healthcare professional or doctor is required to arrange the next dose promptly. The official patient information advises that they will need to schedule the injection as soon as possible.

Q: Is the Haldol Decanoate injection painful?

Official regulatory documents list Injection Site Reaction as a common adverse effect, which means it occurs frequently in patients. However, the regulatory documents do not specifically describe the sensation of pain at the injection site itself.

Q: Can the Haldol shot be used for dementia or for children?

Official labeling contains specific constraints for these groups. The medicine is not approved for treating psychosis related to dementia in elderly patients. Additionally, the safety and effectiveness of Haldol Decanoate have not been established in pediatric patients under 18 years of age.

Q: What should I do if I experience a serious side effect like Neuroleptic Malignant Syndrome?

Neuroleptic Malignant Syndrome (NMS) is a rare but potentially fatal condition detailed in the official warnings. The safety protocol in regulatory labeling mandates that the medication be immediately discontinued and that a healthcare provider be urgently contacted for management if signs of NMS appear.

Advertisements

How should Haldol (Intramuscular) be stored and disposed of?

How to Store and Dispose of Haloperidol (Intramuscular)

Official regulatory guidelines strictly define the conditions for storing and disposing of haloperidol injection to maintain stability and ensure safety.

Storage Requirements

Requirement Description
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Avoid freezing.
Light Protection Keep in the original container and protect from light to prevent degradation.
Safety The medication must be kept in a location out of the reach of children.

Disposal Instructions

Unused or expired haloperidol should be returned to a drug take-back location or utilized through a mail-back program. If these options are unavailable, the medication must be removed from its container, mixed with an undesirable substance (such as coffee grounds or dirt), sealed in a plastic bag or container, and placed in the household trash. Needles and syringes (sharps) must be placed in a dedicated sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Haldol (Intramuscular) found in:

A-Z Index: